Literature DB >> 28942031

The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.

Andrew S Huhn1, D Andrew Tompkins2, Kelly E Dunn2.   

Abstract

BACKGROUND: Relatively little is known regarding the perception of medication-assisted treatments (MATs) and other treatment options amongst individuals that engage in non-medical prescription opioid use. This study surveyed out-of-treatment individuals that misuse opioids to better understand how perceived access to treatment shapes treatment preference.
METHODS: Participants (n=357) were out-of-treatment adults registered as workers on the Amazon Mechanical Turk platform who reported current non-medical prescription opioid use. Participants were surveyed regarding demographics, insurance status, attitudes toward opioid use disorder (OUD) treatments, and self-reported symptoms of OUD.
RESULTS: Participants who were male, did not have health insurance, and knew that counseling-type services were locally available were most likely to first attempt counseling/detox treatments (χ2(6)=30.19, p<0.001). Participants who met criteria for severe OUD, used heroin in the last 30days, knew their insurance covered MAT, and knew of locally available MAT providers were most likely to first attempt MAT (χ2(4)=26.85, p<0.001). Participants with insurance and who knew of locally available physicians were most likely to attempt physician visits without the expressed purpose of MAT (χ2(3)=24.75, p<0.001).
CONCLUSION: Out-of-treatment opioid users were particularly interested in counseling-based services and medical care that could be attained from a primary-care physician. Results suggest that insurance coverage and perceived access to OUD treatment modalities influences where out-of-treatment opioid users might first seek treatment; understanding the factors that shape treatment preference is critical in designing early interventions to effectively reach this population.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Insurance; Medication-assisted treatment (MAT); Opioid use disorder (OUD); Prescription opioid; Treatment accessibility

Mesh:

Substances:

Year:  2017        PMID: 28942031      PMCID: PMC5648596          DOI: 10.1016/j.drugalcdep.2017.08.019

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

1.  Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.

Authors:  Soteri Polydorou; Stephen Ross; Peter Coleman; Laura Duncan; Nichole Roxas; Anil Thomas; Sonia Mendoza; Helena Hansen
Journal:  Psychiatr Serv       Date:  2016-10-17       Impact factor: 3.084

2.  Integrating primary medical care with addiction treatment: a randomized controlled trial.

Authors:  C Weisner; J Mertens; S Parthasarathy; C Moore; Y Lu
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

3.  Untreated opiate addicts. How do they differ from those seeking treatment?

Authors:  B J Rounsaville; H D Kleber
Journal:  Arch Gen Psychiatry       Date:  1985-11

4.  Suicide Deaths With Opioid Poisoning in the United States: 1999-2014.

Authors:  Jennifer Brennan Braden; Mark J Edlund; Mark D Sullivan
Journal:  Am J Public Health       Date:  2017-01-19       Impact factor: 9.308

5.  "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Authors:  Adam R Winstock; Nicholas Lintzeris; Toby Lea
Journal:  Int J Drug Policy       Date:  2010-10-16

6.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

7.  Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?

Authors:  Kenneth Blum; Mark Gold; H Westley Clark; Kristina Dushaj; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-07-27       Impact factor: 2.164

8.  Outcomes for Physicians With Opioid Dependence Treated Without Agonist Pharmacotherapy in Physician Health Programs.

Authors:  Lisa J Merlo; Michael D Campbell; Gregory E Skipper; Corinne L Shea; Robert L DuPont
Journal:  J Subst Abuse Treat       Date:  2016-02-13

9.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.

Authors:  W Ling; C Charuvastra; J F Collins; S Batki; L S Brown; P Kintaudi; D R Wesson; L McNicholas; D J Tusel; U Malkerneker; J A Renner; E Santos; P Casadonte; C Fye; S Stine; R I Wang; D Segal
Journal:  Addiction       Date:  1998-04       Impact factor: 6.526

10.  Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes.

Authors:  D Andrew Tompkins; Patrick S Johnson; Michael T Smith; Eric C Strain; Robert R Edwards; Matthew W Johnson
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

View more
  24 in total

1.  Delivering information about medication assisted treatment to individuals who misuse opioids through a mobile app: a pilot study.

Authors:  Patricia A Cavazos-Rehg; Melissa J Krauss; Shaina J Costello; Alex T Ramsey; Demetrie Petkas; Sean Gunderson; Laura J Bierut; Lisa A Marsch
Journal:  J Public Health (Oxf)       Date:  2020-02-28       Impact factor: 2.341

2.  Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.

Authors:  Sarah A Weicker; Kanna Hayashi; Cameron Grant; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2019-10-25       Impact factor: 4.492

3.  Tobacco and cannabis co-use: Drug substitution, quit interest, and cessation preferences.

Authors:  Erin A McClure; Rachel L Tomko; Claudia A Salazar; Saima A Akbar; Lindsay M Squeglia; Evan Herrmann; Matthew J Carpenter; Erica N Peters
Journal:  Exp Clin Psychopharmacol       Date:  2018-12-17       Impact factor: 3.157

4.  Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.

Authors:  Andrew S Huhn; J Gregory Hobelmann; Justin C Strickland; George A Oyler; Cecilia L Bergeria; Annie Umbricht; Kelly E Dunn
Journal:  JAMA Netw Open       Date:  2020-02-05

5.  Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use.

Authors:  Kaitlyn R Hay; Andrew S Huhn; David Andrew Tompkins; Kelly E Dunn
Journal:  J Addict Med       Date:  2019 Jul/Aug       Impact factor: 3.702

6.  Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal.

Authors:  Andrew S Huhn; D Andrew Tompkins; Claudia M Campbell; Kelly E Dunn
Journal:  Pain Med       Date:  2019-10-01       Impact factor: 3.750

7.  Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.

Authors:  Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

8.  The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.

Authors:  Hannah K Knudsen; Jeanie Hartman; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2022-01-29       Impact factor: 4.492

9.  Differential adoption of opioid agonist treatments in detoxification and outpatient settings.

Authors:  Kelly E Dunn; Andrew S Huhn; Eric C Strain
Journal:  J Subst Abuse Treat       Date:  2019-10-24

10.  Medical Cannabis Use among Adults in the Southeastern United States.

Authors:  Claudia A Salazar; Rachel L Tomko; Saima A Akbar; Lindsay M Squeglia; Erin A McClure
Journal:  Cannabis       Date:  2019-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.